Recent Updates
Recently added Catalysts

TUB-040

Phase 2

NSCLC | Small Molecules | Oncology |Gilead Sciences, Inc.|Trials Updated: Nov 3, 2026

TUB-040 development status

Highest phase Phase 2
Registered trials 3 across 1 sponsor since Mar 2024

TUB-040 target and mechanism

Molecular targetNaPi2b
Target classProtein
ModalitySmall Molecules

Also known as TUB-040

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLEDDMC
Total Trials4
Total Enrollment586

FDA Designations

No designations recorded

TUB-040 clinical trials

TUB-040 · 4 trials · 5 indications

Phase 2 1Phase 1/2 3
NCT07806773Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung CancerNSCLC
NOT YET_RECRUITING80 Analytics
PHASE2NOT YET_RECRUITING
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
NSCLCUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
From enrollment until 30 days after last dose of study drug

Incidence and severity of treatment-emergent adverse events (TEAEs)

Overall Response Rate (ORR)
Enrollment until approximately 80 days since last dose of study drug

Assessment of overall response rate (ORR) by Response Evaluation Criteria for Solid Tumors (RECIST) v1.1 as assessed by the investigator (INV)

Phase 1: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Up to 3 years

Incidence and severity of treatment-emergent adverse events (TEAEs)

Phase 1: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs)
Up to 3 years

Incidence of dose-limiting toxicities (DLTs) at each dose level

Phase 2: Overall Response Rate (ORR)
Up to 3 years

Investigator (INV) assessment of overall response rate (ORR) by Response Evaluation Criteria for Solid Tumors (RECIST) v1.1

To determine the safety and tolerability of TUB-040 in combination with standard ovarian cancer drugs
From enrollment until 30 days after last study drug

Occurrence and severity of treatment-emergent adverse events (TEAEs)

Maximum Tolerated Dose (MTD) of TUB-040 with standard of care (SOC) treatment
Day 1 up to Day 21 of each treatment cycle

Occurrence of DLTs (Dose limiting toxicities) at different dose levels (during first treatment cycle)

Phase 1: Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs)
First dose up to 21 days
Phase 1 and 2a: Percentage of Participants Experiencing Treatment-Emergent Adverse Event (TEAEs)
First dose date up to 30 days post last dose (Up to 3 years)
Phase 2a & 2b: Overall Response Rate (ORR) by Blinded Independent Central Review (BICR)
Up to 3 years

ORR is defined as the percentage of participants who have achieved complete response (CR) or partial response (PR), as assessed by BICR.

Secondary Endpoints

Duration of response (DoR)
Up to approximately 24 months
Disease control rate (DCR)
Up to approximately 24 months
Progression-free survival (PFS)
Up to approximately 24 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
NSCLC Dose 1EXPERIMENTALParticipants will receive TUB-040 administered as an intravenous (IV) infusion on Day 1 of each treatment cycle. Until disease progression, unacceptable toxicity, or withdrawal of consent.
NSCLC Dose 2EXPERIMENTALParticipants will receive TUB-040 administered as an IV infusion on Day 1 of each treatment cycle. Until disease progression, unacceptable toxicity, or withdrawal of consent.
Phase 1: Dose Escalation of TUB-040EXPERIMENTALParticipants will receive escalating doses of TUB-040 to determine recommended Phase 2 dose (RP2D).
Phase 2: Monotherapy of TUB-040EXPERIMENTALParticipants in Phase 2 will receive the recommended dose of TUB-040 monotherapy determined in Phase
Phase 1b Dose EscalationEXPERIMENTALDrug TUB-040 administered in combination with carboplatin (Carbo) and bevacizumab (BEV)
Phase 1: Cohort 1: Dose Escalation in Platinum Resistant Ovarian Cancer (PROC)EXPERIMENTALParticipants will receive escalating doses of TUB-040 every 3 weeks until the disease progresses or the patient has to stop due to side effects.
Phase 1: Cohort 2: Dose Escalation in R/R NSCLC of the adenocarcinoma subtypeEXPERIMENTALParticipants will receive escalating doses of TUB-040 every 3 weeks until the disease progresses or the patient has to stop due to side effects.
Phase 1: Cohort 3: PROC, Combination with Bevacizumab (BEV)EXPERIMENTALParticipants will receive escalating doses of TUB-040 combined with BEV every 3 weeks until the disease progresses or the patient has to stop due to side effects.
Phase 2a: Dose Optimization in PROCEXPERIMENTALParticipants will receive two different dose levels of TUB-040 every 3 weeks until the disease progresses or the patient has to stop due to side effects.
Phase 2b: Dose Expansion in PROCEXPERIMENTALPatients will receive TUB-040 at the safe dose established during dose escalation until disease progression or unacceptable toxicity.

Interventions

NameTypeDescription
TUB-040DRUGAdministered IV
TUB-040 - Dose escalationDRUGTUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle.
TUB-040 - RP2DDRUGTUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle. Dose based on the RP2D
TUB-040 + Carbo + BEVDRUGPh1b: A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered along with carboplatin (Carbo) and bevacizumab (BEV) as an intravenous (IV) solution on day 1 of each treatment cycle for up to 6 cycles.
BevacizumabDRUGAdministered IV
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Key Inclusion Criteria: 1. Adults, male or nonpregnant, nonbreastfeeding female, age ≥18 years at the date of consent. 2. Eastern Cooperative Oncology Group performance status of 0 or 1. 3. Documented radiographic progression on or after the most recent line of anticancer therapy. 4. Life expectanc...

Countries:United StatesBelgiumUkraineGermanyRomaniaSpainUnited Kingdom
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMNov 3, 2026NCT06303505Enrollment: 250 → 334
MEDIUMNov 3, 2026NCT06303505Enrollment: 250 → 334

Frequently asked questions about TUB-040

What is TUB-040 used for?

TUB-040 is an investigational oncology therapy being studied in non-small cell lung cancer, ovarian cancer, and uterine endometrial cancer. It is given alone or in combination with standard chemotherapy and bevacizumab, depending on the tumor type and trial. It is not approved for any use and remains in clinical development.

What does TUB-040 target?

TUB-040 targets NaPi2b, a protein target. It is described as a NaPi2b antibody-drug conjugate, meaning the therapy is directed at NaPi2b-expressing cells. The trials enroll patients with nonsquamous NSCLC, ovarian cancer, and uterine endometrial cancer without a stated biomarker selection requirement.

Who is developing TUB-040?

TUB-040 is being developed by Gilead Sciences, Inc., which trades on Nasdaq under the ticker GILD. The company is running the clinical program across lung, ovarian, and uterine cancer indications in the United States and several European sites.

What phase is TUB-040 in?

TUB-040 is in Phase 2 clinical development. The program includes Phase 1/Phase 2 studies and a dedicated Phase 2 study in nonsquamous non-small cell lung cancer. TUB-040 is investigational and has not been approved by the FDA for any indication.

What clinical trials is TUB-040 in?

TUB-040 is studied in NCT06303505, a first-in-human Phase 1/Phase 2 trial in ovarian cancer and NSCLC that is recruiting, and NCT07736937, a Phase 1/Phase 2 ovarian cancer combination study that is recruiting. Two further studies, NCT07806773 in NSCLC and NCT07743541 in uterine cancer, are not yet recruiting.